Roche Sees Oncology Access Programs Key To Growth
This article was originally published in PharmAsia News
Executive Summary
Against a backdrop of increasing payer scrutiny over the high price tags of new cancer treatments, Roche is looking at two main strategies to ensure access to its therapies in the sector, covering both developed countries and emerging markets.
You may also be interested in...
Where Is The Reward? New Drug Developers See Red In China
A new report on China’s pharma innovation ecosystem paints a grim picture of negative market returns for many novel drugs despite shortened review timelines and government calls to encourage innovation.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.